Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00493441 · ClinicalTrials.gov registry record · Phase 2
AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer
A Phase 2 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Terminated
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT00493441: Clinical Trial Phase 2 study, sponsored by Vertex Pharmaceuticals Incorporated.
NCT00493441 is a Phase 2 study that was terminated before completion, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 28 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00493441, a Phase 2 study, was terminated before completion, sponsored by Vertex Pharmaceuticals Incorporated.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
The study was designed to find the optimum AVN944 dose to use in combination with gemcitabine in patients with pancreatic cancer and see if the combination of the 2 drugs was more effective for treating pancreatic cancer than using gemcitabine alone.
Interventions
- DRUG AVN944
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2007-06 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
Why NCT00493441 stopped before completion
NCT00493441 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 1 intervention - of which AVN944 is the first listed.
NCT00493441 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00493441 about?
NCT00493441 is a clinical study titled "AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer". The study was designed to find the optimum AVN944 dose to use in combination with gemcitabine in patients with pancreatic cancer and see if the combination of the 2 drugs was more effective for treating pancreatic cancer than using gemcitabine alone.
What is the current status of trial NCT00493441?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2007-06. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00493441?
The interventions under investigation include: AVN944 (DRUG).
Who is sponsoring clinical trial NCT00493441?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00493441's enrollment target sits among peer trials
28 1677th of 2000 higher than 304 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia